Home › Migraine › Nebraska
Migraine clinical trials in Nebraska
10 studies for Migraine are looking for participants at sites in Nebraska.
Cities in Nebraska
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- Nebraska Medical Center, Omaha
RecruitingPhase 4
Ages 18 to 70 · All sexes · Updated Nov 13, 2026 · NCT06972056Study of EVO756 in Adults With Migraine
- Papillion Research Center - Avacare Clinical Research, Papillion
RecruitingPhase 2
Ages 18 to 64 · All sexes · Updated Nov 13, 2026 · NCT07616128A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Velocity Clinical Research, Norfolk, Norfolk
- Quality Clinical Research, Inc., Omaha
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Nov 12, 2026 · NCT07816367Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
- Children's Hospital & Medical Center, Omaha
RecruitingPhase 3
Ages 6 to 17 · All sexes · Updated Oct 27, 2026 · NCT04743141Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- Children's Hospital & Medical Center, Omaha
RecruitingPhase 3
Ages 6 to 17 · All sexes · Updated Oct 27, 2026 · NCT04649242Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
- Velocity Clinical Research, Grand Island, Grand Island
- Papillion Research Center/CCT Research, Papillion
RecruitingPhase 3
Ages 6 to 17 · All sexes · Updated Oct 14, 2026 · NCT05156398A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
- Cct Research - Papillion Research Center /ID# 270393, Papillion
RecruitingPhase 3
Ages 12 to 17 · All sexes · Updated Oct 9, 2026 · NCT06810505A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
- Children's Hospital & Medical Center, Omaha
RecruitingPhase 1
Ages 6 to 11 · All sexes · Updated Sep 28, 2026 · NCT06995729Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
- Cognitive Clinical Trials (CCT) - Papillion /ID# 232552, Papillion
RecruitingPhase 3
Ages 6 to 17 · All sexes · Updated Sep 14, 2026 · NCT05125302Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks
- Tri City Research Center, LLC /ID# 278800, Grand Island
RecruitingObservational study
Ages 18 and older · All sexes · Updated Feb 10, 2026 · NCT07310290From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.